首页> 外国专利> ACID DERIVATIVES 2- (8,9-DIOXO-2,6-DIAZABICICLO (5.2.0) NON-1 (7) EN-2-IL) ALQUILFOSFÓNICO AND ITS USE AS ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEIVER (NMDA)

ACID DERIVATIVES 2- (8,9-DIOXO-2,6-DIAZABICICLO (5.2.0) NON-1 (7) EN-2-IL) ALQUILFOSFÓNICO AND ITS USE AS ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEIVER (NMDA)

机译:酸衍生物2-(8,9-二恶英-2,6-二氮杂双胍(5.2.0)非-1(7)EN-2-IL)喹诺酮及其作为N-甲基-D-天冬氨酸受体的拮抗剂NMDA)

摘要

A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R1 is hydrogen, a C1 to C6 alkyl group, a C2 to C7 acyl group, a C1 to C6 alkanesulfonyl group, or a C6 to aroyl group C14; A is alkylene of 1 to 4 carbon atoms or alkenylene of 2 to 4 carbon atoms; R2 and R3 are independently selected from hydrogen, or with the proviso that at least one of R2 and R3 is not hydrogen; R4 and R5 are independently selected from hydrogen, a C1 to C4 alkyl group, a C5 to C7 aryl group, a C6 to C15 alkylaryl group having 5 to 7 carbon atoms in the aryl ring, a C2 to C7 alkenyl group, or C2 to C7 alkynyl group, or R4 and R5 can together form a C3 to C8 spirocarbocyclic ring; R6 is a C1 to C12 linear or branched alkyl group, a C2 to C7 linear or branched alkenyl or alkynyl group, a C5 to C13 aryl group, a C6 to C21 alkylaryl group having 5 to 13 carbon atoms in the aryl moiety ; a 5 to 13 membered heteroaryl group, a 6 to 21 membered alkylheteroaryl group having 5 to 13 members in the heteroaryl moiety, a C4 to C8 cycloalkyl group, a C5 to C16 alkylcycloalkyl group having 4 to 8 atoms of carbon in the cycloalkyl ring; R7 and R8 are independently selected from hydrogen, a linear or branched C1 to C12 alkyl group, a C2 to C7 linear or branched alkenyl or alkynyl group, a C5 to C13 aryl group, a C6 to C21 alkylaryl group having 5 to 13 carbon atoms in the aryl moiety, a 5-13 membered heteroaryl group, a 6 to 21 membered alkylheteroaryl group having 5 to 13 members in the heteroaryl moiety, or R7 and R8 can together form a cycloalkyl or heterocycloalkyl group that it has 4 to 8 carbon atoms in the ring and optionally one or two atoms selected from nitrogen, oxygen or sulfur; wherein any group R1 to R8 having an aryl, heteroaryl, cycloalkyl or heterocycloalkyl moiety may optionally be substituted on the aryl, heteroaryl, cycloalkyl or heterocycloalkyl moiety with 1 to about 5 substituents independently selected from a halogen atom, a cyano group , nitro or hydroxyl, a C1-C6 alkyl group, or a C1-C6 alkoxy group.
机译:式(I)的化合物或其药学上可接受的盐:其中:R 1为氢,C 1至C 6烷基,C 2至C 7酰基,C 1至C 6链烷磺酰基或C 6至芳酰基C 14; A为具有1至4个碳原子的亚烷基或具有2至4个碳原子的亚烯基; R2和R3独立地选自氢,或条件是R2和R3中至少一个不是氢; R 4和R 5独立地选自氢,C 1至C 4烷基,C 5至C 7芳基,在芳环中具有5至7个碳原子的C 6至C 15烷基芳基,C 2至C 7烯基或C 2至C 5。 C7为炔基,或R4和R5可共同形成C3至C8螺碳环; R6为在芳基部分中具有5至13个碳原子的C1至C12直链或支链的烷基,C2至C7直链或支链的烯基或炔基,C5至C13的芳基,C6至C21的烷基芳基; 5至13元杂芳基,在杂芳基部分中具有5至13个成员的6至21元烷基杂芳基,在环烷基环中具有4至8个碳原子的C4至C8环烷基,C5至C16烷基环烷基; R7和R8独立地选自氢,碳原子数为5至13的直链或支链的C1至C12烷基,C2至C7的直链或支链的烯基或炔基,C5至C13的芳基,C6至C21的烷基芳基在芳基部分中,5-13元杂芳基,在杂芳基部分中具有5-13个成员的6-21元烷基杂芳基,或R7和R8可以一起形成具有4-8个碳原子的环烷基或杂环烷基在环中和任选地一个或两个选自氮,氧或硫的原子;其中具有芳基,杂芳基,环烷基或杂环烷基部分的任何基团R1至R8可任选地在芳基,杂芳基,环烷基或杂环烷基部分上被1至约5个独立地选自卤素原子,氰基,硝基或羟基的取代基取代,C 1 -C 6烷基或C 1 -C 6烷氧基。

著录项

  • 公开/公告号ES2350449T3

    专利类型

  • 公开/公告日2011-01-24

    原文格式PDF

  • 申请/专利权人 WYETH LLC;

    申请/专利号ES20040759168T

  • 发明设计人 BUTERA JOHN;BAUDY REINHARDT;

    申请日2004-04-07

  • 分类号A61K31/662;A61K31/675;A61P3/08;A61P3/10;A61P9/10;A61P11;A61P21;A61P21/02;A61P25;A61P27/06;A61P29;A61P29/02;A61P43;C07F9/645;

  • 国家 ES

  • 入库时间 2022-08-21 18:02:48

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号